UPDATE: Spectrum Pharma shares slide 47% premarket after trial of lung cancer treatment misses main goal

Spectrum Pharmaceuticals Inc. shares fell 47% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung…

Read the full article here

Related Articles